RBL2 and small cell lung carcinoma: CRACD is mutated in 11-16% of SCLC patient tumors and cell lines, ranking after RB1 and TP53 but more frequently than RBL2, CREBBP, and EP300 among validated tumor suppressor genes (Supplementary Fig. S1a–d)21–24.